CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
Ziprasidone +1 moredrug
Likely dose
Ziprasidone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01172652
NCT01172652Phase 4Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder

VA Palo Alto Health Care System·interventional·Posted Jul 30, 2010·Updated Apr 8, 2025

In Brief

A Phase 4 clinical trial evaluating Ziprasidone and Placebo for Bipolar Disorder and 2 related conditions. Completed, enrolled 49 participants across 3 sites.

Detailed Summary

The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
CountriesUnited States
CollaboratorsPfizer, University of South Florida, Lindner Center of HOPE

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 30, 2010
Enrollment StartApr 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.9 years ago

Interventions

Ziprasidonedrug

The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.

Placebodrug

Inactive control